Company Overview and News


Add ABMD
to your dashboard

Headline News

Will a 'Huge Tax Cut' Ease Burden for MedTech Players?

20h zacks
After months of discussions, House Republicans has finally passed the much-controversial $1.5-trillion tax-reform bill by a vote of 227 to 205 on Nov 16. The members of the Senate Finance Committee voted 14 to 12 to approve their version of the tax package on Nov 16. This paves the way for the full Senate to hold a debate on the bill once the session resumes post-Thanksgiving. However, Republicans are going to make every effort to get the bill signed by President Trump before Christmas. (66-0)

7 Tech Stocks to Buy That Sport Amazon-Like Growth | InvestorPlace

2017-11-10 investorplace
There’s no doubt that we continue to be in a growth-fueled market. This hasn’t always been the case. In case you’ve forgotten, after the financial meltdown, it was dividend stocks that were the ‘new’ growth stocks. Everyone was scrambling for dividends, and not surprisingly, many stocks began to offer tantalizing dividends. (119-0)

Industry Group Rank Analytics Power Abiomed (ABMD) to Strong Buy

2017-11-08 investorplace
As one of the 785 companies in the GICS Health Care sector Abiomed Inc (NASDAQ:ABMD) is a constituent of the 164 company Health Care Equipment & Supplies GICS industry group within this sector. ABMD has a market value of $8.6 billion which is in the top quarter of its industry group. The stock's current Portfolio Grader score places it 1 among the 164 companies in this industry group, positioning it among the leaders; in the top decile of the sector with a ranking of 1 among the 785 companies in the sector, and number 5 in the nearly 5,000 company Portfolio Grader universe. (19-0)

Your Daily Pharma Scoop: Teva Q3 Results, Boost For RedHill, Clovis Reports Rubraca Sales

2017-11-02 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Please click here or scroll down below to read an important announcement about changes and additions to the daily scoop. (685-3)

Abiomed (ABMD) Looks Good: Stock Adds 7.5% in Session

2017-11-01 zacks
Abiomed, Inc. (ABMD - Free Report) was a big mover last session, as the company saw its shares rise more than 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $168.78 to $181.07 in the past one-month time frame. The company has seen a mixed track record when it comes to estimate revisions of four increases and two decreases over the past one month, while the Zacks Consensus Estimate has moved higher, suggesting that more solid trading could be ahead for Abiomed. (31-0)

Top Ranked Momentum Stocks to Buy for October 31st

2017-10-31 zacks
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, October 31st: (34-0)

HCA Healthcare (HCA) Posts In-Line Q3 Earnings, Keeps View

2017-10-31 zacks
HCA Healthcare, Inc. (HCA - Free Report) reported third-quarter 2017 adjusted earnings of $1.21 per share, which came in line with the Zacks Consensus Estimate. The bottom line declined nearly 25% year over year. HCA Holdings, Inc. Price, Consensus and EPS Surprise (156-0)

ABIOMED's (ABMD) CEO Mike Minogue on Q2 2018 Results - Earnings Call Transcript

2017-10-28 seekingalpha
Good day, ladies and gentlemen and welcome to the Q2, 2018 Abiomed Incorporated Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions]. As a reminder, this conference call may be recorded. (85-0)

Palo Alto Investors, LLC - Current Holdings - Fintel.io

2017-10-12 fintel.io
Palo Alto Investors, LLC has disclosed 38 total holdings in their latest SEC filings. Most recent portfolio value is calculated to be $ 1,752,860,000 USD. Actual Assets Under Management (AUM) is this value plus cash (which is not disclosed). Palo Alto Investors, LLC's top holdings are Clovis Oncology, Inc. (NASDAQ:CLVS) , ABIOMED, Inc. (NASDAQ:ABMD) , United Therapeutics Corp. (NASDAQ:UTHR) , BioMarin Pharmaceutical, Inc. (143-1)

Abiomed Second Quarter Fiscal 2018 Earnings And Conference Call Notification

2017-10-10 devicespace
DANVERS, Mass., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD) announced that on Thursday, October 26, 2017, the Company will release financial results for the second quarter of fiscal 2018. The Company will host a conference call to discuss the results on Thursday, October 26, 2017, at 8:00 a.m. EDT. Michael R. Minogue, Chairman, President and Chief Executive Officer and Robert L. Bowen, former Chief Financial Officer, will host the conference call. (34-0)

Right Time To Buy Medtronic? Know Why The Company Cannot Go Wrong In Cardiac Rhythm And Heart Failure Segment In FY 2018

2017-10-02 seekingalpha
Medtronic has formulated a broad strategy to boost demand for cardiac implantables in the short term. (123-0)

Your Daily Pharma Scoop: Alexion's Canada Pricing, Zogenix, RedHill, Flexion

2017-10-02 seekingalpha
This abridged "Daily Scoop" is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (449-0)

Biotech Forum Daily Digest: Momentum Building For Heron Therapeutics?

2017-09-29 seekingalpha
Very little movement of note within the main biotech indices this week as the sector wraps up the very quiet month of September. (318-4)

Varian Medical Initiates Treatment Using Halcyon System

2017-09-29 zacks
Strengthening its focus in image-guided volumetric intensity modulated radiotherapy to cancer patients, Varian Medical Systems Inc. (VAR - Free Report) recently announced that it has initiated treatment with its recently introduced Halcyon System. Treatment was provided at Penn Medicine to a patient suffering from head and neck cancer. (35-0)

ABIOMED (ABMD) Banks on Impella Platform, Forex a Concern

2017-09-28 zacks
ABIOMED Inc. (ABMD - Free Report) , a leading medical product developer, is focusing heavily on its proprietary Impella Platform to drive customer base. (54-0)

CUSIP: 000365410